Healios
Tokyo
About Healios
Healios aims to commercialize the world’s first pharmaceutical hiPSC derived RPE cell transplantation for treatment of AMD in collaboration with RIKEN, one of the leading research institutes in Japan. The goal of this therapy is to promote the regeneration of retinal function and, consequently, to improve visual function in those affected with retinal degenerative diseases.The significance of the total raised capital fortifies the company’s momentum in the development of therapeutics utilizing the Nobel Prize-winning hiPSC technology and attests its uncompromising commitment to making groundbreaking strides in the field of regenerative medicine.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $31.2M
- Funding stage: IPO
- Last round: Series Unknown (Oct 2013)
- Ticker: tyo:4593
- Website: healios.co.jp
- Phone: +81 3 3544 8730
Industries & Categories
Biotechnology, Health Care, Manufacturing, Medical
Social Profiles
Canonical: https://fsome.com/organization/healios-544013 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.